Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Karex Berhad is the world's largest condom manufacturer by volume, producing over 5 billion condoms annually across facilities in Malaysia, Thailand, and China. The company operates both B2B (supplying global brands and NGOs) and B2C (own brands like ONE, Carex) segments, with significant exposure to government tenders and international development programs. Recent performance reflects margin compression from raw material cost inflation and competitive pricing pressure in commodity condom segments.
Karex operates as a high-volume, low-margin manufacturer leveraging scale economies across automated production lines. Revenue derives from long-term supply contracts with multinational consumer goods companies, competitive bidding for government tenders (UNFPA, USAID programs), and direct-to-consumer sales through retail and e-commerce. Pricing power is limited in commodity segments due to intense competition from Chinese and Indian manufacturers, but the company maintains technical advantages in specialty products (ultra-thin, textured, polyurethane). Gross margins of 31% reflect raw material costs (natural rubber latex, nitrile) representing 40-45% of COGS, with operating leverage constrained by underutilized capacity following pandemic demand volatility.
Major government tender wins or losses (UNFPA, national health ministry contracts worth $10-50M)
Natural rubber latex price movements (direct 40%+ COGS impact with 3-6 month contract lag)
Capacity utilization rates across Malaysia and Thailand facilities (margin inflection above 80%)
USD/MYR exchange rate (revenue 70%+ export-denominated, costs largely MYR-based)
Branded segment growth trajectory and e-commerce penetration in developed markets
Commoditization of standard condom manufacturing with Chinese capacity expansion driving price deflation in tender markets
Regulatory changes in key markets affecting contraceptive access, public health funding, or import/export dynamics
Shift in consumer preferences toward long-acting reversible contraceptives (IUDs, implants) reducing condom market growth in developed economies
ESG and sustainability pressures on natural rubber sourcing requiring supply chain investments
Intense competition from Chinese manufacturers (Guilin Latex, Shandong Geamay) with lower cost structures capturing tender market share
Vertical integration by major consumer brands (Reckitt Benckiser, Church & Dwight) potentially reducing outsourced manufacturing
Private label expansion by retailers compressing branded product margins and shelf space
Negative free cash flow of -3.4% yield indicates cash consumption, potentially requiring external financing or capex reduction
Working capital intensity from long receivable cycles on government contracts straining liquidity despite 1.42x current ratio
Underutilized capacity representing stranded capital with limited near-term return on invested assets (0.5% ROA)
low - Contraceptive demand is relatively non-cyclical with consistent baseline consumption driven by public health programs and essential product positioning. However, discretionary premium product sales and government budget allocations for reproductive health programs show modest correlation to GDP growth in emerging markets. B2B contract manufacturing volumes are stable but pricing reflects competitive dynamics rather than economic cycles.
Moderate sensitivity through two channels: (1) Working capital financing costs for inventory and receivables given 90-120 day payment terms on government contracts, with debt/equity of 0.47x creating modest interest expense exposure; (2) Valuation multiple compression as defensive consumer stocks face competition from risk-free rates. Rising rates increase financing costs but minimal impact on end-demand given product necessity.
Moderate exposure to emerging market sovereign credit risk through government tender receivables (20-25% of revenue), with payment delays possible during fiscal stress. Customer credit quality generally strong for multinational brand partners. Company's own credit access adequate with current ratio of 1.42x, but tightening credit conditions could pressure working capital management.
value - Trading at 1.3x book value with depressed margins (1.6% operating, 0% net) attracts contrarian investors betting on operational turnaround through cost reduction, capacity utilization recovery, and branded segment scaling. Defensive sector positioning appeals during risk-off periods, but growth profile insufficient for growth investors. Recent 40% decline creates potential mean reversion opportunity for value-oriented funds.
moderate-high - Small-cap emerging market exposure ($0.6B market cap, Malaysia listing) creates liquidity-driven volatility. Stock exhibits high beta to MYR currency moves and commodity input costs. Recent 25% quarterly decline indicates elevated volatility during operational stress periods. Tender lumpiness creates quarterly earnings volatility.